MC 1101

Drug Profile

MC 1101

Alternative Names: MC-1101; SB 04

Latest Information Update: 18 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Texas A&M University
  • Developer Changhua Christian Hospital; MacuCLEAR; Mystic Pharmaceuticals; National Taiwan University Hospital
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Dry age-related macular degeneration

Most Recent Events

  • 15 May 2018 Phase-II/III clinical trials in Dry age-related macular degeneration in Taiwan (Ophthalmic) before May 2018
  • 09 Jun 2016 Phase-II/III development is ongoing in USA
  • 19 Apr 2016 Mystic Pharmaceuticals has patent protection for its drug delivery platform technology, VersiDoser® in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top